



A Multidisciplinary Approach to Individualized Patient Care



Induction Therapy for Ph+ B-Cell Acute Lymphoblastic Leukemia

LIVE WEBINAR



Thursday, October 8, 2026
4:30 – 5:30 PM EDT

REGISTER

<https://education.nccn.org/node/98722>

AVAILABLE CREDIT

1.0 AAPA Category 1 CME credit
1.0 ACPE contact hour
1.0 *AMA PRA Category 1 Credit™*
1.0 ANCC contact hour
1.0 CCM clock hour
1.0 Participation

OVERVIEW

The NCCN Guidelines® for ALL provide evidence-based, consensus-driven recommendations to guide cancer prevention, diagnosis, treatment, and supportive care, and are regularly updated to reflect emerging data to support oncology health care professionals in making informed clinical decisions. In addition, this session will provide education on lower intensity and even chemotherapy-free induction therapies, such as blinatumomab combined with a TKI, may help minimize treatment-related adverse effects while maintaining efficacy.

TARGET AUDIENCE

This program is designed to meet the educational needs of physicians/ oncologists, nurse practitioners, nurses, physician associates, pharmacists, and other health care professionals who manage patients with cancer.

FEATURED SPEAKERS FROM NCCN MEMBER INSTITUTION

*UCSF Helen Diller
Comprehensive Cancer Center*



Aaron C. Logan
MD, PhD, MPhil



Mimi Lo
PharmD, BCPS, BCOP

LEARNING OBJECTIVES

- Discuss results of clinical trials assessing lower intensity induction therapy options for newly diagnosed Ph-positive B-ALL.
- Identify treatment-related adverse events of agents commonly used in induction therapy for Ph-positive B-ALL, such as TKIs and blinatumomab.
- Compare and contrast TKI options for newly diagnosed Ph-positive B-ALL.